They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.. The ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.

Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.

They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature Medicine , 2024; DOI: 10.1038/s41591-024-03025-3 Cite ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is marketed under the brand name Keytruda and is currently approved for 3 urothelial cancer indications: ...

If you or a loved one is navigating an advanced bladder cancer diagnosis, visit PADCEV.com† to learn more about Armando and Laura's story and discover more about PADCEV with pembrolizumab as a ...

For 40 years, chemotherapy has been the standard treatment for bladder cancer patients who can tolerate this medicine. However, the results were limited, and lasting results were rare. In recent ...